surmount-1 trial tirzepatide obesity without diabetes SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

21.04

★★★★☆4.8 (126)

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

26.93

★★★★★4.9 (98)

SURMOUNT-1 Trial

22.78

★★★★★5.0 (157)

SURMOUNT-1: Tirzepatide Drastically Reduces Weight in Obese Patients

24.63

★★★★★4.7 (84)

In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight

21.35

★★★★★4.9 (203)

Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT‐1 trial - Hankosky

21.41

★★★★★5.0 (176)

In the SURMOUNT-1 trial (published in NEJM in July 2022) in participants with #obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight.

24.09

★★★★★4.8 (132)